Pretraga

Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1275603

Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)

Chan, Arlene; Delaloge, Suzette; Holmes, Frankie Ann; Moy, Beverly; Iwata, Hiroji; Harvey, J. Vernon; Nicholas, J. Robert; Silovski, Tajana; Gokmen, Erhan; Von Minckwitz, Gunter et al.
Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET) // Journal of Clinical Oncology Meeting Abstract | 2015 ASCO Annual Meeting I
Chicago (IL), Sjedinjene Američke Države, 2015. str. 508-508 (poster, međunarodna recenzija, sažetak, stručni)

CROSBI ID: 1275603 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)

Autori
Chan, Arlene ; Delaloge, Suzette ; Holmes, Frankie Ann ; Moy, Beverly ; Iwata, Hiroji ; Harvey, J. Vernon ; Nicholas, J. Robert ; Silovski, Tajana ; Gokmen, Erhan ; Von Minckwitz, Gunter ; Ejlertsen, Bent ; Chia , Stephen K. L. ; Mansi, Janine ; Barrios, Carlos H. ; Gnant, Michael ; Wong, Alvin ; Bryce, Richard ; Yao, Bin ; Martin, Miguel

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Journal of Clinical Oncology Meeting Abstract | 2015 ASCO Annual Meeting I / - , 2015, 508-508

Skup
2015 ASCO Annual Meeting

Mjesto i datum
Chicago (IL), Sjedinjene Američke Države, 29.05.2015. - 02.06.2015

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
HER2-positive early breast cancer, adjuvant chemotherapy

Sažetak
Neratinib (N) is an irreversible pan-HER tyrosine kinase inhibitor with clinical efficacy in trastuzumab (T) pre-treated HER2-positive (HER2+) metastatic breast cancer. In HER2+ early breast cancer (EBC), a significant proportion of patients (pts) recur with invasive disease despite T- containing adjuvant therapy. ExteNET demonstrates that 12m of N following standard chemotherapy + T improves IDFS and DFS-DCIS at 2y in HER2+ EBC. Diarrhea, the most common AE, was manageable.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA

Ustanove:
Klinički bolnički centar Zagreb

Profili:

Avatar Url Tajana Silovski (autor)

Poveznice na cjeloviti tekst rada:

ascopubs.org

Citiraj ovu publikaciju:

Chan, Arlene; Delaloge, Suzette; Holmes, Frankie Ann; Moy, Beverly; Iwata, Hiroji; Harvey, J. Vernon; Nicholas, J. Robert; Silovski, Tajana; Gokmen, Erhan; Von Minckwitz, Gunter et al.
Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET) // Journal of Clinical Oncology Meeting Abstract | 2015 ASCO Annual Meeting I
Chicago (IL), Sjedinjene Američke Države, 2015. str. 508-508 (poster, međunarodna recenzija, sažetak, stručni)
Chan, A., Delaloge, S., Holmes, F., Moy, B., Iwata, H., Harvey, J., Nicholas, J., Silovski, T., Gokmen, E. & Von Minckwitz, G. (2015) Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET). U: Journal of Clinical Oncology Meeting Abstract | 2015 ASCO Annual Meeting I.
@article{article, author = {Chan, Arlene and Delaloge, Suzette and Holmes, Frankie Ann and Moy, Beverly and Iwata, Hiroji and Harvey, J. Vernon and Nicholas, J. Robert and Silovski, Tajana and Gokmen, Erhan and Von Minckwitz, Gunter and Ejlertsen, Bent and Chia, Stephen K. L. and Mansi, Janine and Barrios, Carlos H. and Gnant, Michael and Wong, Alvin and Bryce, Richard and Yao, Bin and Martin, Miguel}, year = {2015}, pages = {508-508}, keywords = {HER2-positive early breast cancer, adjuvant chemotherapy}, title = {Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)}, keyword = {HER2-positive early breast cancer, adjuvant chemotherapy}, publisherplace = {Chicago (IL), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }
@article{article, author = {Chan, Arlene and Delaloge, Suzette and Holmes, Frankie Ann and Moy, Beverly and Iwata, Hiroji and Harvey, J. Vernon and Nicholas, J. Robert and Silovski, Tajana and Gokmen, Erhan and Von Minckwitz, Gunter and Ejlertsen, Bent and Chia, Stephen K. L. and Mansi, Janine and Barrios, Carlos H. and Gnant, Michael and Wong, Alvin and Bryce, Richard and Yao, Bin and Martin, Miguel}, year = {2015}, pages = {508-508}, keywords = {HER2-positive early breast cancer, adjuvant chemotherapy}, title = {Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET)}, keyword = {HER2-positive early breast cancer, adjuvant chemotherapy}, publisherplace = {Chicago (IL), Sjedinjene Ameri\v{c}ke Dr\v{z}ave} }

Podijeli:





Contrast
Increase Font
Decrease Font
Dyslexic Font
CROSBI koristi kolačiće (cookies) kako bi poboljšao funkcionalnost stranice.